Reacción a "Secondary tumours caused by CAR-T cell therapy very rare, study finds"

This is a retrospective study with the limitations that this entails. It confirms the data previously presented by the University of Pennsylvania. However, the molecular study of the two tumours is of high quality. 

Although the follow-up should be longer, it shows that CAR-T therapy does not develop secondary T-lymphomas at the moment, but that they are different events. The benefit of these treatments far outweighs the risk. 

The main limitation of the study is that the follow-up time for this type of therapy is short.